<DOC>
	<DOCNO>NCT01781871</DOCNO>
	<brief_summary>Severe Pneumococcal disease , bacteremia , meningitis pneumonia , cause significant morbidity mortality otherwise healthy adult population immunocompromised patient . The incidence rate invasive pneumococcal disease considerably high among organ transplant patient healthy individual . Routine immunization Pneumococcal vaccine recommend pretransplant 3-5 year transplantation . The efficacy immunogenicity Pneumococcal polysaccharide vaccine ( Pneumovax® ) suboptimal patient group . The conjugate Pneumococcal vaccine show immunogenic safe subgroup immunocompromised patient . We intend compare immunogenicity repeat dose 13-valent Pneumococcal conjugate vaccine ( Prevenar13® ) exist recommend protocol Pneumococcal polysaccharide vaccine ( Pneumovax® ) adult kidney liver transplant patient .</brief_summary>
	<brief_title>Immunogenicity 13-valent Pneumococcal Conjugate Vaccine Compared Pneumococcal Polysaccharide Vaccine Adult Kidney Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>consecutive new kidney liver transplantation center kidney liver retransplantation center Age &lt; 18 year Previous Pneumococcal vaccination &lt; 3 year ago Febrile illness time vaccination Any sign graft failure rejection time vaccination Splenectomy Pregnancy Critically ill patient due cause , include terminal uncompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pneumococcal vaccination</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>solid organ transplant</keyword>
</DOC>